Comparing telmisartan and losartan for treating diabetic nephropathy and hypertension
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension
This study tests whether telmisartan works better than losartan for people with diabetic kidney disease and high blood pressure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 98 (estimated) |
| Ages | 19 Years to 75 Years |
| Sex | All |
| Sponsor | Chong Kun Dang Pharmaceutical Industry-sponsored |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06431477 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy and safety of telmisartan compared to losartan in patients suffering from diabetic nephropathy and hypertension. It is a multi-center, randomized, open-label study that actively compares the two medications in a controlled environment. The trial aims to determine which medication provides better outcomes for patients with these conditions. Participants will be monitored for their response to treatment and any potential side effects.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 19 to 75 with Type II Diabetes Mellitus who are currently on medication.
Not a fit: Patients with Type I Diabetes Mellitus or those with primary hyper-aldosteronism may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with diabetic nephropathy and hypertension.
How similar studies have performed: Other studies have shown varying results with similar approaches, but this specific comparison is less commonly tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male of Female subjects aged ≥19 or \<75 * Type II Diabetes Mellitus subjects who have been taken medicine * Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF Exclusion Criteria: * Subjects with Type I Diabetes Mellitus * Subjects with Primary hyper-aldosteronism * Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening * Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period * Subjects who received other clinical trial drugs within 28 days of screening visit * Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
Where this trial is running
Seoul
- Severance Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: BeomSeok Kim, M.D, Ph.D — Severance Hospital
- Study coordinator: BeomSeok Kim, M.D, Ph.D
- Email: DOCBSK@yuhs.ac
- Phone: +82-2-2228-5331
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.